How to Buy Newamsterdam Pharma Co Nv Stock
Newamsterdam Pharma Co Nv
NewAmsterdam Pharma Company N. V. , a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases.
Newamsterdam Pharma Co Nv stock last closed at $19.44, down 3.04% from the previous day, and has increased 34.35% in one year. It has overperformed other stocks in the Biotechnology industry by 0.61 percentage points. Newamsterdam Pharma Co Nv stock is currently +245.11% from its 52-week low of $5.63, and -26.22% from its 52-week high of $26.35.
There are currently 89.27M shares of NAMS outstanding. The market cap of NAMS is $1.74B. In the past 24 hours, 222,127 NAMS shares were traded.
How to Buy Newamsterdam Pharma Co Nv Stock
Not sure how to invest in Newamsterdam Pharma Co Nv stock? Here's how.
- Figure out where to buy Newamsterdam Pharma Co Nv stock: You need to decide on an online brokerage, but don't worry - we've tested dozens of online brokerages and apps to help you choose where to buy Newamsterdam Pharma Co Nv stock.
- Sign up for your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Put funds into your brokerage account: Select your method of payment and add your info.
- Analyze Newamsterdam Pharma Co Nv stock: The Newamsterdam Pharma Co Nv ticker symbol is NAMS. Is Newamsterdam Pharma Co Nv stock a good investment? Should you buy shares of NAMS? How do NAMS's underlying business fundamentals look? Do top analysts think Newamsterdam Pharma Co Nv is a good buy? Why has NAMS's stock price moved recently? (Hint: Our stock market analysis tools can help you evaluate if NAMS is a good stock to buy).
- Make your NAMS purchase: Decide if you will purchase NAMS shares at the current market price or use a limit order to purchase NAMS shares at a particular price.
- Get key alerts regarding your NAMS investment: Create a watchlist to monitor your investment in Newamsterdam Pharma Co Nv shares.
Step 1: Figure out where to buy Newamsterdam Pharma Co Nv stock
You need a brokerage account in order to access the NASDAQ market and buy NAMS stock.
Our preferred brokerage: eToro
Based on our experience, eToro is the best online stock brokerage. Here's why:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to world financial markets: From Technology to Industrials, New York to London — you can fill your portfolio with stocks from the world's top stock exchanges.
- Social investing: eToro offers a community with more than 20 million users globally. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by signing up for an account with eToro today.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've selected your brokerage, you'll need to fill out some personal information so you can buy NAMS today.
How to Set Up a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal data to create a new trading account.
- Submit your details by clicking the "Create Account" button. Get started with eToro today
Step 3: Put funds into your brokerage account
Now that you have created your account on the stocks app, you can securely and quickly fund your account:
Watch the walkthrough below to see the process of transferring money into your brokerage account.
Step 4: Analyze Newamsterdam Pharma Co Nv stock
After you have identified the best place to buy Newamsterdam Pharma Co Nv stock, it's crucial to research their stock before you invest, so you actually understand the risk as well as the upside.
Newamsterdam Pharma Co Nv shares at a glance
NAMS Fundamentals
WallStreetZen was built to help part-time investors perform better fundamental analysis.
You can see all of the due diligence checks on NAMS's stock page.
Is NAMS stock properly valued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge NAMS's intrinsic value.
Using relative valuations ratios:
- NAMS may be undervalued based on its P/B ratio of 5.54x, relative to Biotechnology industry P/B ratio of 5.76x
You can access additional valuation research on NAMS's stock here.
A look at NAMS Cashflows and Balance Sheet
Passed Financial Due Diligence Checks:
- NAMS has cash burn of 153523913. It has enough cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the NAMS balance sheet.
- There are more short-term assets than long-term liabilities on the NAMS balance sheet.
- NAMS has a low debt to equity ratio of 0.2.
Failed Financial Due Diligence Checks:
- NAMS has $370.05M in cash and short term investments. This is not enough to cover its annual cash burn of $153.52M.
- NAMS profit margin has gone down from -22% to -1,255.8% in the past year.
Do Wall Street analysts think it's a good time to buy Newamsterdam Pharma Co Nv stock
Out of 4 Equities analysts who give ratings on NAMS, the consensus analyst rating on Newamsterdam Pharma Co Nv is a Strong Buy
It's important to note that analyst forecasts are not recommendations, nor are they financial advice.
You can dive deeper into what analysts are saying on the Newamsterdam Pharma Co Nv stock forecast page.
NAMS Technicals
NAMS Performance Numbers
Last year, NAMS revenue was $15.32M. During the past one years, NAMS's revenue has increased by -85.67% per year. This was slower than the Biotechnology industry average of 28.98%.
Dig into NAMS's earnings and revenue performance here.
What are NAMS executives and large shareholders up to?
In the last year, insiders at NAMS have sold more shares than they have bought.
Johannes Jacob Pieter Kastelein, Chief Scientific Officer of NAMS, was the latest NAMS insider to sell. They sold $4,095,234.00 worth of NAMS stock on Mar 26, 2024.
Get more info about who owns NAMS shares here.
Does NAMS provide a stable income stream?
No, Newamsterdam Pharma Co Nv doesn't provide an income stream by paying out dividends.
What do other traders have to say about NAMS?
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Make your NAMS purchase
You have two main types of orders:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are usually fine. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to ensure you're buying or selling at a particular dollar amount, place a limit order.
Press the Open Trade button and your broker will place your order.
If you want more help with buying stocks on eToro, watch the helpful video below:
Step 6: Get key alerts regarding your NAMS investment
Now that you own some NAMS stock, you'll want to stay up-to-date on your new stock purchase.
Start a watchlist to get notified of the latest news about your NAMS stock.
NAMS Feed
How to Buy Stock in Newamsterdam Pharma Co Nv
To summarize, here are the 6 steps to buy stock in Newamsterdam Pharma Co Nv:
- Figure out where to buy Newamsterdam Pharma Co Nv stock
- Sign up for your brokerage account
- Put funds into your brokerage account
- Analyze Newamsterdam Pharma Co Nv stock
- Make your NAMS purchase
- Get key alerts regarding your NAMS investment
If you require a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you would like to monitor your new investment in Newamsterdam Pharma Co Nv, click the button below.
More Content You May Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.